Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease

Yuri Shelygin, Zoran Krivokapic, S. A. Frolov, I. V. Kostarev, V. L. Astashov, S. V. Vasiliev, A. V. Lakhin, G. V. Rodoman, A. O. Soloviev, Y. M. Stoyko, A. G. Khitaryan, I. A. Nechay

Результат исследований: Научные публикации в периодических изданияхстатья

3 Цитирования (Scopus)

Аннотация

To compare the clinical acceptability of micronized purified flavonoid fraction (MPFF) 1000mg with MPFF 500mg tablets, administered at the same daily dose in patients suffering noncomplicated acute hemorrhoids. Background: MPFF is an established treatment for hemorrhoidal disease. Methods: This was a double-blind, multi-center, randomized study. Patients took either MPFF 1000mgor 500mg tablets for 7 days (daily dose; 3 g over 4 days followed by 2 g over 3 days). Adverse events were recorded in a patient diary. On day 7, anal pain and bleeding were assessed (visual analog scale [VAS] and Dimitroulopoulos scale, respectively). Results: Patients (162) were randomized to MPFF 1000mg (79) and MPFF 500mg (83). No serious adverse events (AEs) occurred; 10 emergent AEs were considered treatment-related (6 for MPFF 1000mg and 4 for 500 mg). Both regimens were associated with significant reduction in anal pain (VAS); 2.37 cm MPFF 1000mg (P
Язык оригиналаанглийский
ЖурналCurrent Medical Research and Opinion
Том32
Номер выпуска11
DOI
СостояниеОпубликовано - 2016
Опубликовано для внешнего пользованияДа

Fingerprint

Подробные сведения о темах исследования «Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease». Вместе они формируют уникальный семантический отпечаток (fingerprint).

Цитировать